Streetbeat News

ACST

Acasti Pharma Inc.

https://www.acastipharma.com

Industry

Biotechnology

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Open

3.43

Mkt cap

34M

Volume

28K

High

3.45

P/E Ratio

-2.36

52-wk high

3.60

Low

3.20

Div yield

N/A

52-wk low

1.98

KeyCorp (NYSE:KEY) shares dropped by 5.4% to $13.10 after reporting Q4 financial results with revenues of $1.538 billion, down 19% Y/Y, but slightly above consensus. Adjusted EPS of 25 cents also exceeded expectations. Other stocks experienced significant movements in Thursday's mid-day session, with various companies reporting gains due to different reasons such as acquisitions, financial results, and analyst upgrades. Conversely, several companies saw their shares fall due to negative news such as voluntary delisting, reverse stock splits, and disappointing earnings guidance.

Portfolio Pulse from Avi Kapoor

January 18, 2024 | 6:08 pm

Acasti Pharma has announced the dosing of the first patient in its GTX-104 STRIVE-ON trial. This marks a significant milestone in the company's clinical development program.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 12:05 pm

Acasti Pharma Inc has filed for a shelf of up to 6.6 million common shares by selling stockholders, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 8:36 pm

Vimal Kavuru, a 10% owner of Acasti Pharma, has reported the purchase of 1,099,103 shares at an average price of $1.19 per share in a Form 4 filing on Wednesday.

Portfolio Pulse from Charles Gross

September 28, 2023 | 9:22 am

Several stocks experienced significant movement in Tuesday's mid-day session. Soleno Therapeutics, Femasys, Intercept Pharmaceuticals, Immunovant, Tharimmune, Acasti Pharma, Cano Health, Bullfrog AI Holdings, Avalo Therapeutics, Adaptive Biotechnologies, Infobird, ARS Pharmaceuticals, Roivant Sciences, Verve Therapeutics, Pliant Therapeutics, Fisker, Planet Green Holdings, BYND Cannasoft Enterprises, Acutus Medical, Aclarion, Vera Therapeutics, Blue Star Foods, NightHawk Biosciences, and Precigen saw gains. Meanwhile, TransCode Therapeutics, Murphy Canyon Acquisition, Davis Commodities, Molekule Group, Polished.com, United Natural Foods, MicroAlgo, Genetron Holdings, Greenfire Resources, Novo Integrated Sciences, Ebix, New Pacific Metals, Biophytis, Roadzen, Akili, FaZe Holdings, MSP Recovery, TROOPS, Sacks Parente Golf, and TD SYNNEX experienced losses.

Portfolio Pulse from Lisa Levin

September 26, 2023 | 4:56 pm

Acasti Pharma Inc (NASDAQ:ACST) shares surged by 34.3% after the company announced $7.5 million in private placement equity financing. The funds will be used for clinical trial expenses, pre-commercial planning, working capital, and other general corporate purposes.

Portfolio Pulse from Henry Khederian

September 26, 2023 | 2:57 pm

Acasti Pharma has announced $7.5 million in private placement equity financing, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 2:27 pm

Acasti Pharma Inc. has announced a $7.5 million private placement equity financing. The funds will be used for general corporate purposes.

Portfolio Pulse from Bill Haddad

September 26, 2023 | 12:01 pm

Acasti Pharma has announced that WuXi Clinical will conduct the STRIVE-ON Phase 3 safety trial for GTX-104 in aSAH patients. The trial aims to evaluate the safety and tolerability of GTX-104 compared to oral nimodipine.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 1:08 pm

Acasti Pharma Inc. (NASDAQ:ACST) has announced a 1-for-6 reverse stock split to regain compliance with the NASDAQ Capital Market's $1.00 minimum bid price continued listing requirement. The split will reduce the number of outstanding common shares from approximately 44.6 million to about 7.4 million and will become effective on July 10, 2023.

Portfolio Pulse from Happy Mohamed

July 07, 2023 | 12:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.